Latest & greatest articles for duloxetine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on duloxetine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on duloxetine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for duloxetine

21. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data

A systematic review of duloxetine and venlafaxine in major depression, including unpublished data A systematic review of duloxetine and venlafaxine in major depression, including unpublished data A systematic review of duloxetine and venlafaxine in major depression, including unpublished data Schueler YB, Koesters M, Wieseler B, Grouven U, Kromp M, Kerekes MF, Kreis J, Kaiser T, Becker T, Weinmann S CRD summary The review concluded that venlafaxine was probably preferred for short-term (...) treatment of major depression compared to duloxetine for efficacy and tolerability and a valid alternative in patients who did not tolerate or respond to selective serotonin reuptake inhibitors and tricyclic/tetracyclic antidepressants. Few studies compared duloxetine and venlafaxine directly. The reliability of the authors’ conclusions is not totally clear. Authors' objectives To evaluate the efficacy and tolerability of two selective serotonin-norepinephrine reuptake inhibitors (SNRIs), duloxetine

DARE.2012

22. Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico

Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico Economic evaluation of duloxetine as a first-line treatment for painful diabetic peripheral neuropathy in Mexico Carlos F, Ramirez-Gamez J, Duenas H, Galindo-Suarez RM, Ramos E Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to evaluate the cost-effectiveness of duloxetine as a first treatment for adults with diabetic peripheral neuropathy and moderate-to-severe pain. The authors concluded that duloxetine was a cost-effective intervention, in Mexico. Overall, the study was adequate

NHS Economic Evaluation Database.2012

23. A Comparative Evaluation of Amitriptyline and Duloxetine in Painful Diabetic Neuropathy: A randomized, double-blind, cross-over clinical trial

A Comparative Evaluation of Amitriptyline and Duloxetine in Painful Diabetic Neuropathy: A randomized, double-blind, cross-over clinical trial 21355098 2011 03 30 2011 07 15 2015 11 19 1935-5548 34 4 2011 Apr Diabetes care Diabetes Care A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial. 818-22 10.2337/dc10-1793 To compare the efficacy and safety of duloxetine and amitriptyline in painful diabetic (...) neuropathy (PDN). In this randomized, double-blind, cross-over, active-control trial, 58 patients received amitriptyline and duloxetine orally once daily at bedtime, each for 6 weeks with optional dose uptitration fortnightly. Single-blinded placebo washout was given for 2 weeks between the two treatments and a single-blinded placebo run-out phase of 4 weeks was given at the end of the treatment period. Pain relief was measured by the patient's global assessment of efficacy, using a visual analog scale

EvidenceUpdates2011 Full Text: Link to full Text with Trip Pro

24. Pain response profile of patients with fibromyalgia treated with duloxetine

Pain response profile of patients with fibromyalgia treated with duloxetine 20551724 2010 06 16 2010 09 22 2015 11 19 1536-5409 26 6 2010 Jul-Aug The Clinical journal of pain Clin J Pain Pain response profile of patients with fibromyalgia treated with duloxetine. 498-504 10.1097/AJP.0b013e3181dee80e This study examined the time course for minimal clinically significant improvement in pain severity during the initial 12 weeks of treatment in patients with fibromyalgia taking duloxetine. Four (...) double-blind, placebo-controlled trials of duloxetine were pooled. Patients received duloxetine 60 mg/d, 120 mg/d, or placebo. Clinically significant treatment response (>or=30% reduction in pain severity on the 24-hour average pain severity of the Brief Pain Inventory scale) was assessed over 12 weeks. At endpoint, 46.9% of duloxetine 60-mg-, 48.6% of duloxetine 120-mg-, and 32.1% of placebo-treated patients (P<0.001 for both doses) had >or=30% improvement on average pain from baseline

EvidenceUpdates2010

25. Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review

Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review Plested M, Budhia S, Gabriel Z CRD summary This review found little evidence available on the treatment of refractory neuropathic pain with pregabalin (...) , lidocaine plasters and duloxetine. The authors' cautious conclusions regarding the evidence from the uncontrolled studies in the review are likely to be reliable. Authors' objectives To assess the efficacy, safety and tolerability of pregabalin, lidocaine plasters and duloxetine in patients with refractory neuropathic pain. Searching MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from January 1998 to December 2008 for relevant studies published in English

DARE.2010

26. Cost-effectiveness of duloxetine: the Stress Urinary Incontinence Treatment (SUIT) study

Cost-effectiveness of duloxetine: the Stress Urinary Incontinence Treatment (SUIT) study Cost-effectiveness of duloxetine: the Stress Urinary Incontinence Treatment (SUIT) study Cost-effectiveness of duloxetine: the Stress Urinary Incontinence Treatment (SUIT) study Mihaylova B, Pitman R, Tincello D, van der Vaart H, Tunn R, Timlin L, Quail D, Johns A, Sculpher M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of duloxetine compared with conservative therapy for women with stress urinary incontinence. The authors concluded that, although there were limitations due to the use of observational data, duloxetine therapy seemed to be cost-effective. The methods were good

NHS Economic Evaluation Database.2010

27. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome

Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome Hauser W, Petzke F, Sommer C CRD summary The authors concluded that there was evidence of the short-term (up to six months) efficacy of duloxetine, milnacipran and pregabalin in fibromyalgia syndrome (...) ; the drugs differed in their effects on fibromyalgia syndrome domains and side-effects. The conclusions about the relative efficacy of drugs were not based on direct comparisons and may not be definitive. Authors' objectives To compare the efficacy and side-effects of duloxetine, milnacipran and pregabalin for the treatment of fibromyalgia syndrome. Searching MEDLINE, SCOPUS and Cochrane Central Register of Controlled Trials (CENTRAL) were searched to May 2009. Information was provided about the search

DARE.2010

28. Analytic model comparing the cost utility of TVT versus duloxetine in women with urinary stress incontinence

Analytic model comparing the cost utility of TVT versus duloxetine in women with urinary stress incontinence Analytic model comparing the cost utility of TVT versus duloxetine in women with urinary stress incontinence Analytic model comparing the cost utility of TVT versus duloxetine in women with urinary stress incontinence Jacklin P, Duckett J, Renganathan A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of duloxetine versus tension-free vaginal tape as the second-line treatment for urinary stress incontinence, using new data on drug discontinuation rates. The authors concluded that tension-free vaginal tape was more cost-effective than duloxetine and was below the recommended

NHS Economic Evaluation Database.2010

29. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland

Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland Benedict A, Arellano J, De Cock E, Baird J Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-utility of duloxetine, compared with selective serotonin re-uptake inhibitors (SSRIs), venlafaxine extended release, and mirtazapine, for the treatment of major

NHS Economic Evaluation Database.2010

30. Cymbalta (duloxetine hydrochloride)

Cymbalta (duloxetine hydrochloride) Drug Approval Package: Cymbalta (duloxetine hydrochloride) NDA #022516 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Cymbalta (duloxetine hydrochloride), 20, 30, and 60 mg Capsules Company: Eli Lilly and Company Application No.: 022516 Approval Date: 11/04/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2010

31. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain

Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain Quilici S, Chancellor J, Lothgren M, Simon D, Said G, Le TK, Garcia-Cebrian A, Monz B CRD summary This review concluded that duloxetine was comparable (...) in efficacy and tolerability to gabapentin and pregabalin for treatment of diabetic peripheral neuropathic pain. The cautious conclusions of this generally well-conducted review appear reliable, but were based on an indirect comparison of a small number of studies. Authors' objectives To evaluate the efficacy and tolerability of drugs for diabetic peripheral neuropathic pain (DPNP) and to perform indirect comparisons of duloxetine with pregabalin, gabapentin and amitriptyline. Searching PubMed, EMBASE

DARE.2009

32. Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods

Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods Girardi P, Pompili M, Innamorati M, Mancini M, Serafini G, Mazzarini L, Del Casale A, Tatarelli R, Baldessarini RJ CRD (...) summary The review found that duloxetine appeared more effective than placebo for acute major depression in adults, and was comparable to selective serotonin-reuptake inhibitors, but that more research is needed. In view of poor reporting of review methods and adverse event outcomes, and lack of statistical evidence that the trials were suitable for pooling, the authors’ conclusions may not be reliable. Authors' objectives To evaluate the efficacy and tolerability of duloxetine for acute major

DARE.2009

36. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial

Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial 18395345 2008 05 20 2008 07 07 2015 11 19 1872-6623 136 3 2008 Jun Pain Pain Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. 432-44 (...) 10.1016/j.pain.2008.02.024 The primary objectives of this study were to assess the efficacy and safety of duloxetine for reducing pain severity in fibromyalgia patients with or without current major depressive disorder. This was a 6-month, multicenter, randomized, double-blind, placebo-controlled study. In total, 520 patients meeting American College of Rheumatology criteria for fibromyalgia were randomly assigned to duloxetine (20 mg/day, 60 mg/day, or 120 mg/day) or placebo, administered once daily

EvidenceUpdates2008

37. A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder

A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder Armstrong EP, Malone DC, Erder MH Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to compare the cost-effectiveness of two branded treatments for major depressive disorder. The authors concluded that escitalopram was more effective and less costly than duloxetine. The methodology appears to have been appropriate and, on the whole, was clearly and transparently reported. The conclusions

NHS Economic Evaluation Database.2008

38. Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK

Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK Beard S M, McCrink L, Le T K, Garcia-Cebrian A, Monz B, Malik R A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study investigated the six-month costs and health benefits of using duloxetine as an additional treatment to the recommended current practice, in the UK, in diabetic patients experiencing peripheral neuropathic pain. The authors concluded that second-line duloxetine created potential cost-savings to the health system

NHS Economic Evaluation Database.2008

39. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data

Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data Wade A G, Fernandez J L, Francois C, Hansen K, Danchenko N, Despiegel N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of escitalopram and duloxetine in the treatment of major depressive disorder (MDD) in the UK. The authors concluded that, from a UK societal perspective, escitalopram led to a reduction in costs and improved clinical outcomes in comparison

NHS Economic Evaluation Database.2008

40. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials

Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials Sultan A, Gaskell H, Derry S, Moore RA CRD summary This review found that duloxetine was equally effective for treatment of painful diabetic neuropathy and fibromyalgia pain (...) and was well tolerated. It was likely to be a useful drug in these difficult-to-treat conditions. Overall this was a clearly reported review and the conclusions are likely to be reliable. Authors' objectives To review the efficacy of duloxetine in the management of painful diabetic neuropathy (PDN) and fibromyalgia. Searching PUBMED, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL) were searched to June 2008. Search terms were reported. Reference lists were searched for additional papers

DARE.2008